NCT06994312View on ClinicalTrials.gov

The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration

NANot yet recruitingINTERVENTIONAL

Enrollment

282

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

December 1, 2028

Conditions

Sepsis-induced Coagulopathy (SIC)

Interventions

DRUG

Nafamostat Mesylate

Anticoagulation with Nafamostat Mesylate for SIC Patients Undergoing Hemofiltration

DRUG

sodium citrate

Anticoagulation with Sodium Citrate for SIC Patients Undergoing Hemofiltration

All Listed Sponsors

lead

The First Hospital of Jilin University

OTHER

NCT06994312 - The Impact of Nafamostat Mesylate on the Prognosis of Patients With Sepsis-Induced Coagulopathy Undergoing Hemofiltration | Biotech Hunter | Biotech Hunter